ALX Oncology (NASDAQ:ALXO) Trading Up 9.1%

ALX Oncology Holdings Inc. (NASDAQ:ALXO)’s share price was up 9.1% on Tuesday . The company traded as high as $15.53 and last traded at $15.53. Approximately 205,332 shares traded hands during trading, a decline of 52% from the average daily volume of 430,118 shares. The stock had previously closed at $14.23.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on ALXO shares. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a report on Friday, April 12th. Stifel Nicolaus restated a “hold” rating and set a $14.00 price target (up previously from $10.00) on shares of ALX Oncology in a report on Friday, March 8th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of ALX Oncology in a report on Wednesday, April 10th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $18.83.

ALX Oncology Stock Performance

The company has a debt-to-equity ratio of 0.05, a quick ratio of 5.24 and a current ratio of 5.24. The firm’s 50-day moving average price is $13.57 and its two-hundred day moving average price is $12.10. The firm has a market capitalization of $775 million, a price-to-earnings ratio of -4.05 and a beta of 1.58.

ALX Oncology (NASDAQ:ALXO) last issued its earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.09). Sell-side analysts predict that ALX Oncology Holdings Inc. will post -3.33 earnings per share for the current year.

Insider Activity

In other news, CEO Jason Lettmann purchased 4,400 shares of ALX Oncology stock in a transaction on Thursday, March 14th. The shares were purchased at an average cost of $11.31 per share, for a total transaction of $49,764.00. Following the completion of the transaction, the chief executive officer now directly owns 171,620 shares in the company, valued at $1,941,022.20. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. In other ALX Oncology news, insider Jaume Pons sold 20,000 shares of the business’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $11.15, for a total value of $223,000.00. Following the completion of the transaction, the insider now directly owns 628,359 shares of the company’s stock, valued at $7,006,202.85. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Jason Lettmann bought 4,400 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was bought at an average cost of $11.31 per share, with a total value of $49,764.00. Following the completion of the purchase, the chief executive officer now owns 171,620 shares of the company’s stock, valued at approximately $1,941,022.20. The disclosure for this purchase can be found here. 50.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On ALX Oncology

A number of institutional investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of ALX Oncology during the fourth quarter worth approximately $28,000. SG Americas Securities LLC bought a new stake in ALX Oncology in the third quarter valued at approximately $48,000. Forefront Analytics LLC bought a new stake in ALX Oncology in the third quarter valued at approximately $66,000. China Universal Asset Management Co. Ltd. increased its stake in ALX Oncology by 445.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company’s stock valued at $86,000 after purchasing an additional 4,706 shares in the last quarter. Finally, J.P. Morgan Private Wealth Advisors LLC bought a new stake in ALX Oncology in the third quarter valued at approximately $96,000. 97.97% of the stock is owned by institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.